Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Last trade$1.86
Day change-$0.02 (-1.06%)
Day range$1.85 – $2.08
Volume1,575,268
Market cap$563M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$563.31M
Price / earnings
—
Price / book
3.12×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.57×
Profitability
Earnings per share
-$0.50
Return on assets
-39.69%
Return on equity
-82.76%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.77×
Quick ratio
1.77×
Cash ratio
0.55×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$145.14M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SANA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$10.94M
$10.78M
$11.46M
$12.19M
$10.29M
$10.34M
$11.48M
$17.28M
Research and development
-$29.45M
$54.64M
$37.15M
$19.58M
$33.23M
$40.02M
$39.15M
$40.58M
Total operating expenses
-$18.51M
$65.42M
$48.61M
$61.2M
$43.52M
$94.98M
$50.63M
$50.87M
Operating income
$18.51M
-$65.42M
-$48.61M
-$61.2M
-$43.52M
-$94.98M
-$50.63M
-$50.87M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$20.4M
-$63.64M
-$47.21M
-$58.83M
-$42.15M
-$93.8M
-$49.39M
-$49.07M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$20.4M
-$63.64M
-$47.21M
-$58.83M
-$42.15M
-$93.8M
-$49.39M
-$49.07M
Net income attributable to common shareholders
$20.4M
-$63.64M
-$47.21M
-$58.83M
-$42.15M
-$93.8M
-$49.39M
-$49.07M
EBITDA
$21.48M
-$63.19M
-$46.22M
-$58.15M
-$40.32M
-$47.51M
-$46.98M
-$45.17M
Basic earnings per share
$0.07
-$0.22
-$0.17
-$0.21
-$0.16
-$0.39
-$0.21
-$0.21
Diluted earnings per share
$0.07
-$0.22
-$0.17
-$0.21
-$0.16
-$0.39
-$0.21
-$0.21
Recent news
Company coverage with links to the original publishers.
Sana Biotechnology (SANA) stock has declined 14.8% over the past week but formed a hammer chart pattern suggesting potential trend reversal. Rising analyst optimism and a 20.7% increase in consensus EPS estimates over 30 days, combined with a Zacks Rank #2 (Buy) rating, indicate improving prospects for the biotechnology company.
Kailera Therapeutics completed the largest biotech IPO since 2021, raising $625 million at $16 per share. The company is developing GLP-1-based obesity treatments, with its lead candidate ribupatide in Phase 3 trials. Kailera enters a competitive $200 billion obesity market dominated by Eli Lilly and Novo Nordisk, with promising early data showing up to 12.1% weight loss in oral formulation trials.
U.S. stock futures rose on Tuesday following Monday's rally, with major indices trading higher. Vice President JD Vance signaled potential progress in Iran nuclear talks if Tehran meets U.S. demands. Investors await March producer price index data. Key movers include Sana Biotechnology surging 20% on Mayo Clinic collaboration, ChargePoint jumping 6.63% on insider buying, and Chevron declining despite a Venezuela oil production agreement. Professor Jeremy Siegel warns of near-term market caution due to rising oil prices and money growth concerns.
Sana Biotechnology published research in Nature Biotechnology demonstrating successful in vivo gene editing of human hematopoietic stem cells using fusogen technology, potentially transforming treatment for diseases like sickle cell and beta thalassemia without conditioning chemotherapy.
Stock promoter Eric Jackson highlighted Sana Biotechnology as a potential '100-bagger' stock, citing falling interest rates, cooling inflation, and biotech sector revival as key catalysts.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.